Metabolic syndrome in hypertensive patients was associated with a higher rate of total cardiovascular events compared to those without the syndrome (55.4 vs 35.8 events/1000 person-years; P=0.009).
Cohort (n=1,007)
Does the presence of metabolic syndrome increase the risk of cardiovascular morbidity and mortality in hypertensive individuals?
Metabolic syndrome significantly increases the risk of cardiovascular morbidity and mortality in hypertensive patients, with risk scaling by the number of metabolic components.
Effect estimate: 75% higher risk
Absolute Event Rate: 55.4% vs 35.8%
p-value: p=.009
BACKGROUND: Although the metabolic syndrome (MetS) is associated with adverse cardiovascular disease (CVD) risk in the general population, it is not clear whether its existence is independently associated with CVD in hypertensives. We investigated the presence of MetS in subjects with hypertension and its impact on the incidence of CVD. METHODS: We prospectively investigated 1007 hypertensive individuals. The MetS was assessed using the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria. The incidence of fatal and nonfatal cardiovascular events was ascertained during a median follow-up period of 2.1 years. RESULTS: The prevalence of MetS was 42.1% (39.0% in men and 44.7% in women). In addition to hypertension, four MetS components were present in 3.6% of the individuals, three in 13.7%, two in 24.8%, and only one in 33.7%. The incidence of cardiac, cerebrovascular, and total cardiovascular events/1000 person-years was higher among MetS subjects than among those without (31.0% v 21.3%, P = .050, 25.5% v 13.7%, P = .045, and 55.4% v 35.8% P = .009, respectively). After adjustment, MetS subjects had higher risk for cardiac, cerebrovascular, and total cardiovascular events (by 72%, 90%, and 75%, respectively). Hypertensive subjects with three or more components of MetS had threefold higher risk for cardiac events, 2.59 for cerebrovascular, and 2.26 for total cardiovascular events compared with those with no other component. CONCLUSIONS: The MetS is a significant predictor of cardiovascular morbidity and mortality. The clustering of three or more components of the syndrome in addition to hypertension recognizes a population of even higher cardiovascular risk independently of other traditional risk factors.
ANDREADIS et al. (Tue,) conducted a cohort in Hypertension (n=1,007). Metabolic syndrome vs. Absence of metabolic syndrome was evaluated on Total cardiovascular events (75% higher risk, p=.009). Metabolic syndrome in hypertensive patients was associated with a higher rate of total cardiovascular events compared to those without the syndrome (55.4 vs 35.8 events/1000 person-years; P=0.009).